Details of Disease

General Information of Disease (ID: DISFSC09)

• Disease Name: Burn and burn infection
• Disease Class: ND90-NE2Z: Burn and burn infection
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISFSC09: Burn and burn infection
• ICD Code:
  ICD-11: ICD-11: ND90-NE2Z
  ICD-10: ICD-10: T20-T25

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
D2A21	DMYJ2QB	Phase 3	NA	[1]
ESS	DMIRZNK	Phase 2	NA	[2]
Neuprex	DM1BOKQ	Phase 2	Peptide	[3]
StrataGraft	DMWD1L8	Phase 1/2	NA	[4]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Putrescine	DMWE6V1	Discontinued in Phase 2	Small molecular drug	[5]
Vibrilase	DMO8FQT	Discontinued in Phase 1	NA	[6]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020 May;19(5):311-332.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT00462904) Pharmacokinetic Response to BPI in Burns. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT00618839) StrataGraft Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects. U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2388).
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015283)